A subscription to JoVE is required to view this content. Sign in or start your free trial.
MAPS technology has been developed to scrutinize the targetome of a specific regulatory RNA in vivo. The sRNA of interest is tagged with a MS2 aptamer enabling the co-purification of its RNA partners and their identification by RNA sequencing. This modified protocol is particularly suited for Gram-positive bacteria.
Although small regulatory RNAs (sRNAs) are widespread among the bacterial domain of life, the functions of many of them remain poorly characterized notably due to the difficulty of identifying their mRNA targets. Here, we described a modified protocol of the MS2-Affinity Purification coupled with RNA Sequencing (MAPS) technology, aiming to reveal all RNA partners of a specific sRNA in vivo. Broadly, the MS2 aptamer is fused to the 5’ extremity of the sRNA of interest. This construct is then expressed in vivo, allowing the MS2-sRNA to interact with its cellular partners. After bacterial harvesting, cells are mechanically lysed. The crude extract is loaded into an amylose-based chromatography column previously coated with the MS2 protein fused to the maltose binding protein. This enables the specific capture of MS2-sRNA and interacting RNAs. After elution, co-purified RNAs are identified by high-throughput RNA sequencing and subsequent bioinformatic analysis. The following protocol has been implemented in the Gram-positive human pathogen Staphylococcus aureus and is, in principle, transposable to any Gram-positive bacteria. To sum up, MAPS technology constitutes an efficient method to deeply explore the regulatory network of a particular sRNA, offering a snapshot of its whole targetome. However, it is important to keep in mind that putative targets identified by MAPS still need to be validated by complementary experimental approaches.
Hundreds, perhaps even thousands of small regulatory RNAs (sRNAs) have been identified in most bacterial genomes, but the functions of the vast majority of them remain uncharacterized. Overall, sRNAs are short non-coding molecules, playing major roles in bacterial physiology and adaptation to fluctuating environments1,2,3. Indeed, these macromolecules are at the center of numerous intricate regulatory networks, impacting metabolic pathways, stress responses but also virulence and antibiotic resistance. Logically, their synthesis is triggered by specific environment stimuli (e.g., nutrient starvation, oxidative or membrane stresses). Most sRNAs regulate multiple target mRNAs at the post-transcriptional level through short and non-contiguous base pairing. They usually prevent translation initiation by competing with ribosomes for translation initiation regions4. The formation of sRNA:mRNA duplexes also often results in the active degradation of the target mRNA by recruitment of specific RNases.
The characterization of an sRNA targetome (i.e., the whole set of its target RNAs) allows the identification of the metabolic pathways in which it intervenes and the potential signal it answers to. Consequently, the functions of a specific sRNA can generally be inferred from its targetome. For this purpose, several in silico prediction tools have been developed such as IntaRNA and CopraRNA5,6,7. They notably rely on sequence complementarity, pairing energy and accessibility of the potential interaction site to determine putative sRNA partners. However, prediction algorithms do not integrate all factors influencing base-pairing in vivo such as the involvement of RNA chaperones8 favoring sub-optimal interactions or the co-expression of both partners. Due to their inherent limitations, the false positive rate of prediction tools remains high. Most experimental large-scale approaches are based on the co-purification of sRNA:mRNA couples interacting with a tagged RNA binding protein (RBP)6,9. For example, the RNA Interaction by Ligation and sequencing (RIL-seq) method identified RNA duplexes co-purified with RNA chaperones such as Hfq and ProQ in Escherichia coli10,11. A similar technology called UV-Crosslinking, Ligation And Sequencing of Hybrids (CLASH) was applied to RNase E- and Hfq-associated sRNAs in E. coli12,13. Despite the well-described roles of Hfq and ProQ in sRNA-mediated regulation in multiple bacteria8,14,15, sRNA-based regulation seems to be RNA chaperone-independent in several organisms like S. aureus16,17,18. Even if the purification of RNA duplexes in association with RNases is feasible as demonstrated by Waters and coworkers13, this remains tricky as RNases trigger their rapid degradation. Hence, the MS2-Affinity Purification coupled with RNA Sequencing (MAPS) approach19,20 constitutes a solid alternative in such organisms.
Unlike above-mentioned methods, MAPS uses a specific sRNA as bait to capture all interacting RNAs and hence does not rely on the involvement of an RBP. The entire process is depicted in Figure 1. In brief, the sRNA is tagged at the 5’ with the MS2 RNA aptamer that is specifically recognized by the MS2 coat protein. This protein is fused with the maltose binding protein (MBP) to be immobilized on an amylose resin. Therefore, MS2-sRNA and its RNA partners are retained on the affinity chromatography column. After elution with maltose, co-purified RNAs are identified using high-throughput RNA sequencing followed by bioinformatic analysis (Figure 2). The MAPS technology ultimately draws an interacting map of all potential interactions occurring in vivo.
MAPS technology was originally implemented in the non-pathogenic Gram-negative bacterium E. coli21. Remarkably, MAPS helped identify a tRNA-derived fragment specifically interacting with both RyhB and RybB sRNAs and preventing any sRNA transcriptional noise to regulate mRNA targets in non-inducing conditions. Thereafter, MAPS has been successfully applied to other E. coli sRNAs like DsrA22, RprA23, CyaR23 and GcvB24 (Table 1). In addition to confirming previously known targets, MAPS extended the targetome of these well-known sRNAs. Recently, MAPS has been performed in Salmonella Typhimurium and revealed that SraL sRNA binds to rho mRNA, coding for a transcription termination factor25. Through this pairing, SraL protects rho mRNA from the premature transcription termination triggered by Rho itself. Interestingly, this technology is not restricted to sRNAs and can be applied to any type of cellular RNAs as exemplified by the use of a tRNA-derived fragment26 and a 5’-untranslated region of mRNA22 (Table 1).
MAPS method has been also adapted to the pathogenic Gram-positive bacterium S. aureus19. Specifically, the lysis protocol has been widely modified to efficiently break cells due to a thicker cell wall than Gram-negative bacteria and to maintain RNA integrity. This adapted protocol already unravelled the interactome of RsaA27, RsaI28 and RsaC29. This approach gave insights into the crucial role of these sRNAs in regulatory mechanisms of cell surface properties, glucose uptake, and oxidative stress responses.
The protocol developed and implemented in E. coli in 2015 has been recently described in great detail30. Here, we provide the modified MAPS protocol, which is particularly suitable for studying sRNA regulatory networks in Gram-positive (thicker cell wall) bacteria whether non-pathogenic or pathogenic (safety precautions).
1. Buffers and media
2. Safety issues
3. Plasmid construction
NOTE: For cloning purposes, it is crucial to first identify the boundaries of the endogenous sRNA. The pCN51-P3 and pCN51-P3-MS2 plasmids are described in Tomasini et al. (2017)27. The P3 promoter allows high expression of the sRNA in a cell-density-dependent manner (i.e., when bacteria enter the stationary phase of growth). Many staphylococcal sRNAs accumulate during this growth phase.
4. Bacteria harvesting
CAUTION: This step involves handling of pathogenic bacteria (see step 2).
5. Mechanical cell lysis
CAUTION: Following steps must be performed on ice and buffers must be at 4 °C. Use gloves and take all precautions to protect samples from RNases.
6. Column preparation
CAUTION: Be careful not to allow the amylose resin to dry. If needed, seal the column with an end-cap. Prepare all the solutions before starting the affinity purification.
7. MS2-affinity purification (Figure 1)
8. RNA extraction of collected fractions (CE, FT, W and E)
9. Analysis of MS2-affinity purification by Northern blot36
10. Preparation of the samples for RNA sequencing
NOTE: This step only concerns RNAs extracted from E and CE fractions.
11. RNAseq data analysis (Figure 2)
The representative results originate from the study of RsaC targetome in S. aureus29. RsaC is an unconventional 1,116 nt-long sRNA. Its 5’ end contains several repeated regions while its 3’ end (544 nt) is structurally independent and contains all predicted interaction sites with its mRNA targets. The expression of this sRNA is induced when manganese (Mn) is scarce, which is often encountered in the context of host immune response. Using MAPS technology, we identified several ...
A modified protocol for Gram-positive bacteria
The initial protocol of MAPS was developed to study sRNA interactome in the model organism E. coli20,30. Here, we describe a modified protocol which is suitable for the characterization of sRNA-dependent regulatory networks in the opportunistic human pathogen S. aureus and is certainly transposable to other Gram-positive bacteria, pathogenic or not.
The authors have nothing to disclose.
This work was supported by the “Agence Nationale de la Recherche” (ANR, Grant ANR-16-CE11-0007-01, RIBOSTAPH, and ANR-18-CE12- 0025-04, CoNoCo, to PR). It has also been published under the framework of the labEx NetRNA ANR-10-LABX-0036 and of ANR-17-EURE- 0023 (to PR), as funding from the state managed by ANR as part of the investments for the future program. DL was supported by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 753137-SaRNAReg. Work in E. Massé Lab has been supported by operating grants from the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC), and the National institutes of Health NIH Team Grant R01 GM092830-06A1.
Name | Company | Catalog Number | Comments |
1.5 mL microcentrifuge tube | Sarstedt | 72.690.001 | |
15 mL centrifuge tubes | Falcon | 352070 | |
2 mL microcentrifuge tube | Starstedt | 72.691 | |
2100 Bioanalyzer Instrument | Agilent | G2939BA | RNA quantity and quality |
250 mL culture flask | Dominique Dutscher | 2515074 | Bacterial cultures |
50 mL centrifuge tubes | Falcon | 352051 | Culture centrifugation |
Absolute ethanol | VWR Chemicals | 20821.321 | RNA extraction and purification |
Allegra X-12R Centrifuge | Beckman Coulter | Bacterial pelleting | |
Ampicilin (amp) | Sigma-Aldrich | A9518-5G | Growth medium |
Amylose resin | New England BioLabs | E8021S | MS2-affinity purification |
Anti-dioxigenin AP Fab fragment | Sigma Aldrich | 11093274910 | Northern blot assays |
Autoradiography cassette | ThermoFisher Scientific | 50-212-726 | Northern blot assays |
BamHI | ThermoFisher Scientific | ER0051 | Plasmid construction |
BHI (Brain Heart Infusion) Broth | Sigma-Aldrich | 53286 | Growth medium |
Blocking reagent | Sigma Aldrich | 11096176001 | Northern blot assays |
CDP-Star | Sigma Aldrich | 11759051001 | Northern blot assays (substrate) |
Centrifuge 5415 R | Eppendorf | RNA extraction and purification | |
Chloroform | Dominique Dutscher | 508320-CER | RNA extraction and purification |
DIG-RNA labelling mix | Sigma-Aldrich | 11277073910 | Northern blot assays |
DNase I | Roche | 4716728001 | DNase treatment |
Erythromycin (ery) | Sigma-Aldrich | Fluka 45673 | Growth medium |
FastPrep device | MP Biomedicals | 116004500 | Mechanical lysis |
Guanidium Thiocyanate | Sigma-Aldrich | G9277-250G | Northern blot assays |
Hybridization Hoven Hybrigene | Techne | FHB4DD | Northern blot assays |
Hybridization tubes | Techne | FHB16 | Northern blot assays |
Isoamyl alcohol | Fisher Scientific | A/6960/08 | RNA extraction and purification |
LB (Lysogeny Broth) | Sigma-Aldrich | L3022 | Growth medium |
Lysing Matrix B Bulk | MP Biomedicals | 6540-428 | Mechanical lysis |
MicroPulser Electroporator | BioRad | 1652100 | Plasmid construction |
Milli-Q water device | Millipore | Z00QSV0WW | Ultrapure water |
NanoDrop spectrophotometer | ThermoFisher Scientific | RNA/DNA quantity and quality | |
Nitrocellulose membrane | Dominique Dutsher | 10600002 | Northern blot assays |
Phembact Neutre | PHEM Technologies | BAC03-5-11205 | Cleaning and decontamination |
Phenol | Carl Roth | 38.2 | RNA extraction and purification |
Phusion High-Fidelity DNA Polymerase | New England Biolabs | M0530 | Plasmid construction |
pMBP-MS2 | Addgene | 65104 | MS2-MBP production |
Poly-Prep chromatography column | BioRad | 7311550 | MS2-affinity purification |
PstI | ThermoFisher Scientific | ER0615 | Plasmid construction |
Qubit 3 Fluorometer | Invitrogen | 15387293 | RNA quantity |
RNAPro Solution | MP Biomedicals | 6055050 | Mechanical lysis |
ScriptSeq Complete Kit | Illumina | BB1224 | Preparation of cDNA librairies |
Spectrophotometer Genesys 20 | ThermoFisher Scientific | 11972278 | Bacterial cultures |
SpeedVac Savant vacuum device | ThermoFisher Scientific | DNA120 | RNA extraction and purification |
Stratalinker UV Crosslinker 1800 | Stratagene | 400672 | Northern blot assays |
T4 DNA ligase | ThermoFisher Scientific | EL0014 | Plasmid construction |
TBE (Tris-Borate-EDTA) | Euromedex | ET020-C | Northern blot assays |
ThermalCycler T100 | BioRad | 1861096 | Plasmid construction |
Tween 20 | Sigma Aldrich | P9416-100ML | Northern blot assays |
X-ray film processor | hu.q | HQ-350XT | Northern blot assays |
X-ray films Super RX-N | FujiFilm | 4741019318 | Northern blot assays |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved